Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years

NCT00539981 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00539981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2007
Completion date
May 28, 2008
Enrollment
4,648 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

influenza